Solventum announced today that management will participate in a fireside chat at the Piper Sandler Healthcare Conference on Tuesday, Dec. 2, 2025, beginning at approximately 10:00 a.m. EST in New York, NY.

Solventum announced today it has entered into a definitive agreement to acquire Acera Surgical, a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.

Solventum announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock.

Solventum announced today reported sales increased 0.7%; organic sales increased 2.7%; expects full year organic sales growth to be at the high end of +2.0% to +3.0% range; increases full year adjusted earnings per share outlook to $5.98 to $6.08 and announces 4-year 'Transform for the Future' initiative. See below.